The tweet was deleted by the author.
But we saved everything 🙂.
Immuneering has named Andrew Gengos as its new chief financial officer, signaling a strategic move for the company as it advances its pipeline.
Gengos, who previously served at Terns Pharmaceuticals, will steer finance strategy, investor relations, and business development at Immuneering. His appointment comes as the company progresses the atebimetinib program in the Phase 3 MAPKeeper 301 trial for first-line pancreatic cancer and expands its broader portfolio.
Immuneering has recently attracted industry attention after Mizuho analyst Graig Suvannavejh highlighted its pancreatic cancer data at ASCO26. Earlier this year, the company reported a 17.3 month median overall survival in a Phase 2a trial for first-line pancreatic cancer, exceeding standard care, according to topline results. These developments reinforce the company's focus on advancing its atebimetinib program.